Clinical Case of Diagnosis of Eosinophilic Esophagitis in A Patient Who Was Suffering for A Long Time with Severe Bronchial Asthma and Receiving Therapy with A Gerd (Dupilumab)

We presented a clinical case of diagnosing eosinophilic esophagitis in a patient suffering from severe asthma for a long time and receiving therapy with genetically engineered biological drugs: Dupilumab. Difficulties in diagnosis are associated, on the one hand, with the need for histological verification of the diagnosis, and on the other hand, with the heterogeneity of the manifestations of the disease. The frequent coexistence of EoE and other allergic diseases emphasizes the unity of pathogenetic pathways united by mucosal immune reactions. Our clinical case demonstrates the possibility of diagnosing EoE in the absence of characteristic complaints and endoscopic picture in a patient with polyvalent allergies and a long history of severe asthma. Timely use of effective therapy helps prevent remodeling of the esophageal wall with the development of strictures, which can significantly worsen the patient’s quality of life.

1. Durrani S.R., Mukkada V.A., Guilbert T.W. Eosinophilic Esophagitis: an Important Comorbid Condition of Asthma? Clinical reviews in allergy & immunology. 2018;55(1):56-64. doi: 10.1007/s12016-018-8670-7.

2. Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Clinical recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of eosinophilic esophagitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(6):84–98. doi: 10.22416/1382-4376-2018-28-6-84-98. [in Russian].

3. Hill D.A., Grundmeier R.W., Ramos M. ey al. Eosinophilic Esophagitis Is a Late Manifestation of the Allergic March. The journal of allergy and clinical immunology. In practice. 2018;6(5):1528-1533. doi: 10.1016/j.jaip.2018.05.010

4. Arias Á., Lucendo A.J. Epidemiology and risk factors for eosinophilic esophagitis: lessons for clinicians. Expert review of gastroenterology & hepatology. 2020;14(11):1069-1082. doi: 10.1080/17474124.2020.1806054

5. Grando M., De Pauli S., Miotti G. et al. Adult eosinophilic esophagitis and advances in its treatment. World journal of methodology. 2023; 13(3): 59-66. doi: 10.5662/wjm.v13.i3.59

6. Khokhar D., Marella S., Idelman G. et al. Eosinophilic esophagitis: Immune mechanisms and therapeutic targets. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2022;52(10):1142-1156. doi: 10.1111/cea.14196.

7. Maslenkina K.S., Motylev E.N., Gushchin M.Yu. et al. Pathomorphological criteria and features of the immune response in eosinophilic esophagitis and reflux esophagitis. Archives of Pathology. 2024; 86(1):5–12. doi: 10.17116/patol2024860115. [in Russian].

8. Bakulina N.V., Simanenkov V.I., Vorobyov S.L. et al. Eosinophilic esophagitis and IgG4-related esophageal lesions. Therapeutic archive. 2020;92(8):100-107 doi: 10.26442/00403660.2020.08.000792. [in Russian].

9. Paraskevova A.V., Shelkovnikova I.I., Lapina T.L. et al. A 68-year-old patient and a 52-year-old female patient with eosinophilic infiltration of the esophagus. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):62-74. doi: 10.22416/1382-4376-2017-27-4-62-74. [in Russian].

10. Hait E.J., McDonald D.R. Impact of Gastroesophageal Reflux Disease on Mucosal Immunity and Atopic Disorders. Clinical reviews in allergy & immunology. 2019;57(2):213-225. doi: 10.1007/s12016-018-8701-4

11. Rank M.A., Sharaf R.N., Furuta G.T. et al. Technical Review on the Management of Eosinophilic Esophagitis: A Report from the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters. Gastroenterology. 2020;158:1789–1810. doi: 10.1053/j.gastro.2020.02.039.

12. Frandsen L.T., Westmark S., Melgaard D. et al. Effectiveness of PPI treatment and guideline adherence in 236 patients with eosinophilic oesophagitis-Results from the population-based DanEoE cohort shows a low complication rate. United European gastroenterology journal. 2021;9:910–918. doi: 10.1002/ueg2.12146.

13. Al-Horani R.A., Chiles R. First Therapeutic Approval for Eosinophilic Esophagitis. GastroenterolInsights 2022; 13: 238- 244. doi: 10.3390/gastroent13030024.

14. Massironi S., Mulinacci G., Gallo C. et al. Mechanistic Insights into Eosinophilic Esophagitis: Therapies Targeting Pathophysiological Mechanisms. Cells. 2023;12(20):2473. doi: 10.3390/cells12202473

15. Rieder F., Nonevski I., Ma J. et al. T-Helper 2 Cytokines, Transforming Growth Factor Β1, and Eosinophil Products Induce Fibrogenesis and Alter Muscle Motility in Patients with Eosinophilic Esophagitis. Gastroenterology. 2014;146:1266–1277. doi: 10.1053/j.gastro.2014.01.051.